Interpretation of clot‐based lupus anticoagulant assays—Normalizing clotting time against different denominators

The endpoint for all lupus anticoagulant (LA) assays is a clotting time in seconds. This study aimed to clarify the use of normalizing clotting time to ratio and how the use of different denominators is relevant.

[1]  T. Ortel,et al.  Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis , 2020, Journal of thrombosis and haemostasis : JTH.

[2]  D. Isenberg,et al.  Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management , 2020, Thrombosis Research.

[3]  D. Isenberg,et al.  16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends , 2020, Lupus.

[4]  H. Cohen,et al.  Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis , 2020, Journal of thrombosis and haemostasis : JTH.

[5]  G. Moore,et al.  Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test‐specific cut‐off than index of circulating anticoagulant , 2017, Research and practice in thrombosis and haemostasis.

[6]  G. Moore.  Reference interval mean clotting times should not be used to calculate lupus anticoagulant mixing test ratios unless they match the normal pooled plasma clotting time. , 2017, Thrombosis research.

[7]  R. Malmström,et al.  Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting , 2017, Thrombosis and Haemostasis.

[8]  G. Moore.  Current Controversies in Lupus Anticoagulant Detection , 2016, Antibodies.

[9]  P. Meroni,et al.  The challenges of lupus anticoagulants , 2016, Expert review of hematology.

[10]  I. Pabinger,et al.  Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). , 2015, Blood.

[11]  G. Moore.  Commonalities and contrasts in recent guidelines for lupus anticoagulant detection , 2014, International journal of laboratory hematology.

[12]  G. Moore.  Recent Guidelines and Recommendations for Laboratory Detection of Lupus Anticoagulants , 2014, Seminars in Thrombosis and Hemostasis.

[13]  G. Moore,et al.  Lupus anticoagulant detection: out of control? , 2013, International journal of laboratory hematology.

[14]  Ian Mackie,et al.  Guidelines on the investigation and management of antiphospholipid syndrome , 2012, British journal of haematology.

[15]  M. Rodger,et al.  The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. , 2011, Thrombosis research.

[16]  A. Tripodi,et al.  Testing for lupus anticoagulants: all that a clinician should know , 2009, Lupus.

[17]  S. Rangarajan,et al.  Further evidence of false negative screening for lupus anticoagulants. , 2008, Thrombosis research.

[18]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[19]  Kenneth P. Parker,et al.  Testing for what? , 2003, IEEE Des. Test Comput..

[20]  T. Barbui,et al.  Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. , 2003, Blood.